ArticleVeterinary medicine and science2025
Impact of Mannitol on Left Atrial Pressure in Dogs With Mitral Regurgitation.
Article in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMannitol has been proven effective in treating cerebral oedema, owing to its osmotic diuretic effect. However, its potential to transiently increase plasma volume raises uncertainties about its impact on dogs with mitral avalve insufficiency.
objectivesThis study aimed to investigate the effects of mannitol on haemodynamics and cardiac load in dogs with experimentally induced mitral regurgitation (MR), with a particular focus on the potential adverse effects of high doses of mannitol.
methodsWe used implantable telemetry to monitor MR dogs for 12 consecutive hours, recording and comparing the dynamic changes in their mean left atrial pressure (mLAP) and heart rate at different doses of mannitol (low [0.5 g/kg], medium [1 g/kg] and high [2 g/kg]).
resultsCompared with that in the control group, the low- and medium-dose groups demonstrated a proclivity towards increased mLAP after administration, but without statistical significance. The high-dose group exhibited an immediate increase in the mLAP after administration (p < 0.001), followed by a gradual return to baseline 1 h later.
conclusionsThis study provides crucial reference data for the use of mannitol in treating MR. It is particularly important to exercise caution when administering high doses of mannitol to dogs with advanced stages of MR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.